23 Set 2022 | Press release
TechnoPhage announced the spin-off of T-Oncology AG, which will focus on the development of Antibody Drug Conjugates (ADCs), based on the proprietary Small Domain Antibodies platform (TechnoBodies), for the treatment of cancer. TechnoBodies technology has been...
8 Ago 2022 | Press release
The continued growth of Technophage from a small biotech into a clinical-stage biopharma has resulted in the company making the Financial Times’ 1000 Fastest Growing Companies in Europe for the in 2022. This rating is co-created by the Financial Times and...